Description: Cardiol Therapeutics Inc is a Canada-based company engaged in the pharmaceutical business sector. The Company is focused on the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer. It has research programs focused on development of nanotherapeutics to treat heart failure underway. The Company invests in development of formulations for three medical markets: commercializing a line of purity pharmaceutically-manufactured cannabidiol products in the market for medical cannabinoids; development of nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs for the treatment of heart failure, a cause of death and hospitalization, and pursuing an immunotherapeutics program commencing with a cancer immunotherapeutic in combination with cannabinoids for treating Glioblastoma Multiforme.
Home Page: www.cardiolrx.com
CRDL Technical Analysis
2265 Upper Middle Road East
Oakville,
ON
L6H 0G5
Canada
Phone:
289 910 0850
Officers
| Name | Title |
|---|---|
| Mr. David G. Elsley M.B.A., MBA | Pres, CEO & Director |
| Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, M.B.A., MBA | CFO, Corp. Sec. & Director |
| Mr. Bernard Lim B.Sc. | Chief Operating Officer |
| Dr. Andrew Warwick Hamer M.D. | Chief Medical Officer & Head of R&D |
| Trevor Burns | Investor Relations |
Exchange: TO
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0314 |
| Price-to-Sales TTM: | 1273.7856 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |